Scandinavian Biopharma continues to expand and has now recruited Dilek Merdol as new head of QC. Dilek has a PhD in infectious biology and has 20 years’ experience in R&D and laboratory operations. She comes from a position as manager in the unit of Clinical Microbiology at Karolinska University Laboratory.
“I am looking forward to the challenges and opportunities that this fast-growing company can offer. It will be exciting to lead and develop the QC department together with my experienced co-workers. It feels like a great opportunity to be part of the development of a vaccine that can save the lives of hundreds of thousands of children in low- to middle income countries and also make a difference for millions of travelers ”, says Dilek Merdol.
“Dilek will add valuable expertise thanks to her experience from laboratory operations and she will contribute with valuable competence and energy and advance our QC department. The new full-time position as head of QC fits perfectly for the stage of development that we are currently in, says Nils Carlin, CSO at Scandinavian Biopharma.
We are a Swedish specialty biopharma company developing the first vaccine for protection against diarrhoea caused by ETEC in both travellers and endemic populations.
Along with the vaccine development we are experts in marketing and sales of specialty biopharma products in Europe.